SciSparc stock surges after N2OFF shareholders approve MitoCareX acquisition

N2OFF shareholders have approved the acquisition of SciSparc's majority-owned subsidiary, MitoCareX Bio Ltd., causing SciSparc stock to surge 33%. Under the agreement, N2OFF will acquire MitoCareX for $700,000 cash and an equity exchange representing 40% of N2OFF's fully diluted capital for the sellers, with additional financing proceeds and milestone-based equity potential. This transaction, expected to close in October 2025, strategically positions N2OFF in the growing cancer therapeutics market through MitoCareX's novel cancer therapy development.

Analysis

The approval by N2OFF, Inc. (NITO) shareholders for the acquisition of MitoCareX Bio has triggered a significant positive revaluation of SciSparc Ltd. (SPRC), evidenced by a 33% surge in its stock price. The transaction structure is complex, involving an initial $700,000 cash payment to SciSparc, but more importantly, it transforms the sellers into major equity holders with a 40% stake in N2OFF's fully diluted capital. This arrangement aligns long-term interests and provides further upside through milestone-based equity issuances of up to 25% and a share in financing proceeds capped at $1.6 million. For N2OFF, this acquisition represents a strategic pivot into the high-growth cancer therapeutics market, which is projected to expand from $194.1 billion in 2024 to $344.1 billion by 2031. N2OFF's commitment to fund MitoCareX's operations, including an initial $1 million investment, signals a firm intent to develop its newfound pipeline in novel cancer therapies. The deal effectively allows SciSparc to monetize a subsidiary while retaining significant exposure to its future success through a substantial holding in the newly focused N2OFF.

Key Decisions for Investors

• Investors in SciSparc (SPRC) should recognize that the company's value is now significantly tied to the performance of N2OFF (NITO), given its 40% initial stake and potential future milestone payments, making SPRC a partial proxy for NITO's success in the oncology space.
• For N2OFF investors, the acquisition introduces substantial growth potential in the large cancer therapeutics market but also brings significant integration and execution risk associated with early-stage biotech development; monitoring N2OFF's ability to fund and advance the MitoCareX pipeline is now critical.
• With the transaction expected to close in October 2025, interested parties should watch for the satisfaction of final closing conditions as the next key catalyst, while long-term valuation for both entities will heavily depend on MitoCareX achieving its R&D milestones.